Therapeutic Areas
- Allergic rhinitis
- Allergic rhinoconjunctivitis
- Rhinosinusitis
- Chronic urticaria
They affect ~25% of the world’s population, with an increasing prevalence. Existence of unmet needs Existence of needs not covered by current treatments.
We are working on new molecules in advanced preclinical phases, and new combinations in late-stage pharmaceutical development.
- Ulcerative colitis
- Eosinophilic oesophagitis
In the EU, gastrointestinal inflammatory disease chronically affects around 2.5M people, with an increasing prevalence.
We work on a promising portfolio of new molecules and development of new innovative formats.
- Vitamin D Deficiency
- Osteoporosis
- Autoimmune Diseases
>50% de la población española tiene carencia de vitamina D (c.80% en mayores de 65 años). Déficit de vitamina D asociado a osteoporosis, enf. autoinmunes, cardiovasculares, etc.
We work on the research into new molecules and new formats in advanced stages of pharmaceutical development.
- Painful muscle spasms
- Hemorrhoid symptoms
Musculoskeletal pain is responsible for more than 30% of work absenteeism, affecting between 13% and 47% of the population.
We are working on expanding our portfolio with a novel combination, in an advanced state of pharmaceutical development.
